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CONDENSED ABSTRACT 
The non-inferiority design is used extensively in current clinical research, but its 
complex features may hamper the appropriate interpretation of such trials. Thus, 
understanding the pillars of non-inferiority design is indispensable. We discuss 
fundamental concepts regarding the design and interpretation of non-inferiority trials 
and then explore some common methodological criticism by analysing a sample of 
contemporary coronary stent trials. Finally, we give an overall perspective in order to 
enhance the design and conduct of future trials.    
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ABBREVIATIONS AND ACRONYMS: 
NI = Non-inferiority 
CI = Confidence interval 
CONSORT = Consolidated Standards of Reporting Trials 
FDA = Food and Drug Administration 
TAVR = Transcatheter aortic valve replacement 
SAVR = Surgical aortic valve replacement 
RR = Relative risk 
OR = Odds ratio 
HR = Hazard ratio 
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MANUSCRIPT 
Over the past 15 years there has been an increased use of non-inferiority (NI) designs 
for randomized controlled trials, especially in cardiology(1,2). This is due in part to the 
challenge that new treatments have to compete with pre-existing effective standard 
treatments, making placebo-controlled trials unethical in many situations. NI trials 
assess the hypothesis that a new treatment is not unacceptably worse, regarding a 
specific efficacy (or safety) criterion, than a standard treatment, usually an active 
control. 
This design has facilitated the approval of many new drugs and devices proposed as 
valuable alternatives to standard therapy, given an anticipated ancillary benefit (e.g. 
fewer side effects, higher drug adherence or lower procedural risk). Despite their 
common use, these studies remain poorly understood due to their statistical complexity 
and difficulties of interpretation. Moreover, criticism has been raised concerning their 
various design limitations(3,4). In this paper, we aim to provide insight regarding the 
essential concepts required for appropriate interpretation of NI trials, as well as focus on 
some controversies illustrated with recent examples, especially trials of coronary stents.   
 
PRINCIPLES OF A NON-INFERIORITY TRIAL 
Classic superiority clinical trials propose new treatments to replace (previous treatment 
as comparator) or improve (placebo as comparator) current standard practice by 
outperforming it in terms of major efficacy and/or safety clinical endpoints. Conversely, 
a NI trial proposes an alternative treatment to be as good as (not inferior to) the existing 
standard, usually with an ancillary benefit(5–7). These are not necessarily opposing 
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facets: for example, transcatheter aortic valve replacement (TAVR) initially emerged as 
a treatment for aortic stenosis in inoperable patients, replacing medical treatment by 
demonstrating superiority in clinical outcomes including mortality(8). At the same time, 
TAVR was also proposed as an alternative to surgical aortic valve replacement (SAVR), 
the gold standard treatment, offering ancillary benefits (less invasive approach, 
avoidance of cardiopulmonary bypass and shorter ICU stay) and potentially comparable 
clinical outcomes. Consequently, TAVR was tested in operable patients with several 
surgical risk profiles and proved to be not inferior in hard clinical outcomes, including 
mortality and stroke, to SAVR(9,10). A NI trial may also include the hypothesis of 
superiority as a primary outcome, once the first hurdle of establishing non-inferiority is 
achieved e.g liraglutide in the LEADER study(11). 
Comparing a new treatment to a recognised standard requires justification on grounds of 
a compelling mechanism of action and a positive framework of pre-trial evidence. For 
example, the pivotal NI trial ABSORB III(12) proposed biorresorbable scaffolds 
(AbsorbTM, Abbott Vascular) as an alternative to drug-eluting stents, using the rationale 
of an extremely appealing concept (non-permanent vessel scaffolding) and favourable 
experiences in small clinical cohorts(13).  
In practice, this general model is sometimes adopted for slightly different purposes e.g. 
aiming for a combination of non-inferior efficacy (NI design for composite ischemic 
event) and improved safety (superiority design for major bleeding) as in the OASIS- 5 
study(14); excluding a safety concern in a treatment with known efficacy (sitagliptin 
and cardiovascular safety in the TECOS study(15)); making head-to-head comparisons 
of treatments currently in clinical practice (cryoballoon or radiofrequency ablation for 
paroxysmal atrial fibrillation in the FIRE AND ICE study(16)); and so-called “me-too” 
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trials, which introduce similar medications or devices with subtle improvements, but not 
substantial advantages (coronary drug-eluting stent trials(12,17–24)).  
 
DEFINING A RELEVANT DIFFERENCE: THE NON-INFERIORITY MARGIN 
The non-inferiority margin, delta (∆), is a critical component when considering the 
definition of “not being worse” in NI trials. This NI parameter defines the boundary not 
to be exceeded by the upper confidence limit of the difference between study 
treatments´ event rates (measured in absolute percentages or ratios i.e. RR, OR, HR). 
The NI margin is fixed in advance and should be clinically justified. It ideally represents 
the smallest evidence of inferiority, which if true would mean that the new treatment is 
unacceptable. In the PARTNER 2 trial comparing TAVR with SAVR, a relative NI 
margin (Hazard Ratio) of 1.20 was chosen for the composite endpoint of death and 
disabling stroke. The study showed a HR of 0.89 (95% CI 0.73 to 1.09) for TAVR and 
therefore the authors stated that TAVR appeared not inferior to the surgical therapy for 
this pre-specified margin(10).   
The magnitude of a NI margin critically determines the size of a trial (i.e. trial size 
increases inversely to the square of the margin) and is of foremost importance when 
interpreting its results. Too conservative (narrow) a margin may lead to a large and 
unfeasible trial with the risk of inconclusive results for truly non-inferior therapies. On 
the other hand, too liberal a margin may allow moderately inferior therapies to enter 
clinical practice based on insufficient evidence, potentially becoming inappropriate new 
standards for future non-inferiority trials. If the latter occurs repeatedly, a paradox may 
emerge when the active control becomes no better than placebo (so-called `biocreep´ 
phenomenon(25)). When feasible, the margin is chosen based on the known effect of 
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the active control versus placebo (e.g. choose half of this as margin). However, in 
stent/TAVI trials the margin seems a more arbitrary choice influenced by what is a 
realistic sample size. 
In order to preserve the active control effect, it is key to choose the best available 
standard for the active control as well as selecting a reasonable and justified non-
inferiority margin. Choice of too liberal (large) margin and hence too small a trial 
increases the risk of false claims of non-inferiority. Such a large margin may be 
convenient for trial size but clinically unacceptable. Both statistical and clinical 
judgement are required when choosing the non-inferiority margin and several key 
factors should be taken into consideration (Table 1). Detailed technical approaches to 
appropriately choose the NI margin and caveats to bear in mind are discussed 
elsewhere(3,5,6,25). 
 
ASSESSING TREATMENTS´ DIFFERENCES 
From a statistical viewpoint, a NI trial is primarily interested in only one direction of 
potential treatment difference, namely whether the experimental therapeutic measure is 
(or is not) worse than the current standard(25). However, these trials can still go on to 
superiority test (two-sided) once the NI criterion is met. Therefore, several different 
scenarios may occur each with their own interpretation (Figure 1).   
For a new treatment to be considered non-inferior (i.e. achieve statistical significance 
for the test of non-inferiority) the confidence interval of the observed difference with 
the active control must exclude the NI margin (Figure 1, situations A, B, C). If this 
occurs the authors can reasonably assume that the true effect is as good as the current 
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standard for the given margin. The possibility of showing that the experimental 
treatment is significantly better remains a legitimate objective within these trials´ 
designs(3,6): that is, it is legitimate to test superiority in a trial once the non-inferiority 
criterion are met, as occurs in Figure 1, situation A. Similar to a superiority trial where 
a `negative´(non-significant) outcome does not mean the treatments are equivalent, it is 
important to understand that failing to demonstrate non-inferiority in a NI trial may 
mean the trial is inconclusive as in Figure 1, situations D and E where the CI indicates 
that the data are compatible with both no difference and a difference size delta. This 
may well occur if the trial is too small. An infrequent situation (situation F) may occur 
if the interval of the difference excludes the NI margin and at the same time does not 
include the zero difference (i.e. absolute 0 difference or relative risk 1). In this case, the 
therapy is significantly inferior, but not to the extent of the pre-defined NI margin. 
Alternatively, the chosen NI margin may have been unrealistically large.  
 
POWERING THE TRIAL TO DETECT DIFFERENCES 
The null and alternative hypothesis in NI trials are switched around compared to a 
classical superiority trial. The trial is powered to be able to reject the null hypothesis 
that the experimental treatment has inferiority delta compared to the active control i.e. 
the trial should provide compelling evidence to favour the alternative hypothesis of no 
true treatment difference.  
Power calculations to determine a NI trial size (not presented here) follow similar 
principles to superiority trials re type I and type II errors, with subtle nuances. For the 
specific NI margin chosen it is generally assumed that a one-sided 2.5% or two-sided 
5% alpha risk (equivalent to consider a one-sided 97.5% CI or two-sided 95% CI 
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respectively), and preferably a 10% beta risk (90% power) to ensure confidence in 
establishing non-inferiority if truly the two treatments have identical efficacy. For 
device trials, there are instances where a 5% one-sided alpha risk has been 
permitted(26). This practice (with the consequent CI 14% narrower) makes it easier (too 
easy?) to claim non-inferiority and reduces the required trial size by 18%. It is generally 
not accepted for drug trials and is becoming less common for device trials. Sometimes 
trialists opt for 80% power (rather than 90%)(26) since it reduces the required trial size 
by 25%, though of course this carries a higher risk of failing to demonstrate non-
inferiority.  
The two other key parameters in trial size calculation are the magnitude of the 
difference to be detected (NI margin) and the expected event rate in the control group. 
The latter is important since an overestimation of the event rate can lead to an 
underpowered trial. This estimation usually comes from previous trials, meta-analyses 
or registries. Therefore, if the new trial´s population differs from the population from 
which the expected event rate was derived the observed event rate may also differ(3,7). 
In cases where the observed event rate is substantially lower than expected, an interim 
analysis may lead to a decision to increase trial size to regain power, though this is not 
always achievable. The OASIS-5 trial was designed to assess non-inferiority of 
fondaparinux compared to enoxaparin in an efficacy composite event (death, 
myocardial infarction, or refractory ischemia at nine days) in 16,000 patients with acute 
coronary syndrome. A blinded review of the first 4000 patients indicated that the overall 
event rate was lower than expected. Therefore, the inclusion criteria were modified so 
that patients under the age of 60 years were required to have both an elevation of 
biomarkers and ischemic electrocardiographic changes, and the sample size was 
increased to 20,000 patients(14).  
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CHOICE OF AN ABSOLUTE OR RELATIVE NON-INFERIORITY MARGIN  
Suppose an absolute difference (% of events) is chosen instead of a risk ratio (RR, OR, 
HR) as the NI margin. Then if the observed event rate in the control group is lower than 
expected, the fixed absolute NI margin becomes proportionally wider (more permissive) 
in respect to the observed event rate in the control group(3,6).  
For instance, imagine a trial design anticipated an event rate of 10% in the active control 
arm (as for the experimental arm) and chose an absolute NI margin of 3.5%. This is 
equivalent to a relative risk NI margin = (3.5% + 10%) / 10% = 1.35; that is a maximum 
relative increase of 35% of events accepted as non-inferior for the experimental arm.  
1000 patients in each arm were recruited to provide at least 85% power. Suppose the 
trial´s observed event rates were 5.5% and 6.0% in the active control and experimental 
arms respectively, yielding an absolute risk difference 0.5% with two-sided 95% CI 
(one-sided alpha 2.5%) from -1.5 to 2.5%. This meets the pre-defined non-inferiority 
criterion (upper CI bound < 3.5%) with a significant p value for non-inferiority (p 
<0.05).  
The problem here, is that the corresponding relative risk increase 6.0% / 5.5% = 1.09 
with a 95% CI from 0.76 to 1.56. That is, the upper limit far exceeds the relative margin 
of 1.35 considered in the design. The statistical test for non-inferiority was `tricked´ by 
choosing an absolute NI margin in the beginning, that in the end is equivalent to a 
relative risk margin of 1.64 [(3.5% + 5.5%) / 5.5%] which appears unacceptably large.  
Hence, in this hypothetical case, an absolute NI margin in combination with a lower 
than expected event rates permitted higher relative rate increases to be accepted as non-
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inferior. If instead a relative NI margin of 1.35 was chosen, it would have led to the 
inability to claim non-inferiority. The trial would be declared inconclusive (similar to 
scenario E of Figure 1). 
Using relative indices has the advantage of guarding against unrealistically `optimistic´ 
claims of non-inferiority if the control group event rate is lower than expected, but in 
such circumstances a trial will need to be larger to achieve its aims. That is, the power 
of a NI trial with an appropriate relative risk NI margin requires a certain number of 
primary events. Hence, if the event rate is lower than expected, the number of patients 
needs to be increased accordingly.  
 
INTENTION TO TREAT AND PER PROTOCOL ANALYSIS 
High quality trial conduct is always sought, but is particularly important in NI trials. 
Low adherence, crossovers, loss to follow-up and misclassification of endpoints tend to 
make two treatments´ results appear similar and therefore bias towards the non-
inferiority hypothesis(7).  
In this regard, intention-to-treat (ITT) analysis, standard in superiority trials as the most 
robust outcome analysis, may facilitate similarity between treatments making it easier to 
demonstrate non-inferiority. For instance, in a trial with many crossovers the differences 
are diluted and thus the ITT analysis will show artificially similar outcomes between 
groups. Conversely, per-protocol (PP) or as-treated (AT) analysis may preserve subtle 
treatment differences thus reducing the risk of false claims of non-inferiority. Thus, 
PP/AT analyses are of particular value in the reporting for NI trials, despite their risk of 
potential bias e.g. compliers may be an unrepresentative subset of patients. Moreover, 
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ITT preserves the advantages of randomisation and provides a result closer to the 
overall effect that the treatment would have in a real-life scenario. Ideally, both analysis 
should be reported in order to evaluate the consistency of the results(3,6). For example, 
PROCEED II study used a NI design to compare two different methods of preserving 
human donor hearts (i.e. cold storage versus ex-vivo perfusion). The primary endpoint 
of patient and graft survival was analysed and reported in ITT, PP and AT populations, 
demonstrating noninferiority as a consistent finding in all three analyses(27). 
 
OFFICIAL STATEMENTS 
Guidelines regarding the conduct and reporting of NI trials have been published by 
several groups including the Consolidated Standards of Reporting Trials (CONSORT) 
Statement(28), the FDA(29), and the European Medicines Agency (EMA)(30). All 
recommend outlining the rationale for choosing a noninferiority design. Other important 
recommendations from both CONSORT and the FDA include an explanation of how 
the study hypothesis is incorporated into the design, how the participants´ interventions 
and outcomes were chosen, a description of the statistical methods including how the 
sample size was calculated, and how the study design affects its interpretation and 
conclusions(28,29).  
 
The importance of a NI margin’s influence on trial outcomes is reflected in all 
guidelines. CONSORT(28) recommend specifying the rationale for the choice of the NI 
margin along with whether the margin is based on an absolute or relative scale. The 
EMA is concerned with both the absolute and relative efficacy of the new treatment, 
although do not provide specific recommendations(30). 
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Finally the CONSORT guidelines recommend clarification on whether the results are 
based on an ITT or PP analysis or both, along with commenting on the stability of the 
results with respect to the different analysis(28). While the FDA guidelines discuss the 
advantages and disadvantages of an ITT analysis they do not provide definitive 
recommendations(29). 
 
CURRENT METHODOLOGICAL CONCERNS  
Despite efforts from regulatory agencies and the CONSORT group to guide trialists in 
adequately conducting and reporting non-inferiority trials, some commonly recognised 
deficiencies persist(1,31,32), in all fields including cardiology(2). 
Arbitrarily large NI margins and/or inflated expected event rates have previously been 
outlined as sources of bias towards potentially false claims of non-inferiority of a new 
treatment(3,4,6). Both parameters critically determine sample size and therefore study 
costs and hence it is tempting for trialists to inflate them in order to reduce the sample 
size. Absence of justification in the selection of the NI margin has also been extensively 
noted(1,2,28). 
A noteworthy use of NI design concerns comparison of alternative stents for 
percutaneous coronary interventions. Following the introduction of drug-eluting stents, 
rates of restenosis and clinical events have decreased considerably, and thus new stents 
are unlikely to show superiority(33). We now perform a systematic analysis of the 
reporting of NI trials comparing new generation drug eluting stents (DES) to second 
generation DES. 
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AN EXAMPLE OF RECENT CORONARY STENT TRIALS 
Based on a Medline search, we identified 9 NI trials comparing new generation stents to 
second generation stents, published in high impact journals during 2010 to 2015 (12,17–
24). All trials had similar target populations and a common primary endpoint (with 
subtle variations among them): Target Lesion Failure (TLF), defined as a composite of 
cardiac death, target vessel myocardial infarction and target lesion revascularization. 
An overview of these studies (Table 2) reveals the following: most (7/9) trials reported 
the source justifying the expected control TLF rate (asterisks). In all studies, except one, 
the observed event rate was lower than expected, markedly so in some trials. Note all 
trials had an absolute risk difference as the chosen NI margin, expressed in terms of 
absolute percentage of events. Remarkably, the NI margins varied from 2.5% to 8.6% 
(median 3.6%) and only two trials justified the selection of this value (asterisks). 
Moreover, all trials but ABSORB III assumed a 5% one-sided alpha risk for testing non-
inferiority. 
As mentioned above, one consequence of using an absolute NI margin and having a 
lower event rate than expected is that it permits higher relative rate increases to be 
accepted as non-inferior. We aimed to demonstrate this by calculating the corresponding 
relative risk NI margins used in these studies [relative NI margin = (event rate + 
absolute NI margin) / event rate]. When plotting the observed absolute risk difference 
with CI (two-sided 90 or 95% according to their design) along with the pre-defined 
absolute NI margins (Figure 2, left panel) all studies show non-inferiority for the new 
treatment. However, when plotting the relative risk between groups with CI’s and the 
corresponding calculated relative NI margin (Figure 2, right panel) used in the design, 
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the trial findings become more inconclusive; only 4 out of 9 trials consistently 
demonstrated non-inferiority using this relative risk criterion. 
The previous analyses were done on an intention-to-treat basis, which was the primary 
reported outcome in all the trials. Table 3 shows the same analysis performed in a per 
protocol or as-treated basis (reported by 7 of the 9 trials and showing similar 
conclusions) and performed assuming the recommended one-sided alpha 2.5% versus 
5% assumed in the majority of the studies.  
This review illustrates how fixed absolute NI margins in combination with substantial 
(apparently unexpected) decreases in event rates can artificially enhance claims of non-
inferiority. Furthermore, large and potentially unjustified NI margins (either absolute or 
relative) facilitate this bias. The variability evident in the choice of the NI margins 
across trials reflects a lack of consensus which needs clearer resolution. Moreover, 
alpha risk assumed in most of these studies does not strictly comply with current 
recommendations.  
 
A CONSTRUCTIVE APRRAISAL FOR FUTURE NON-INFERIORITY TRIALS 
As previously discussed, too wide a NI margin translates into excessive tolerability for 
the experimental treatment, whereas too narrow a NI margin may prove too tough a 
hurdle prohibiting some truly non-inferior therapies from entering clinical practice. The 
magnitude of the NI margin critically determines the size of the trial; thus, its choice 
requires a realistic balancing of scientific goals with an achievable sample size. 
Given the importance of the pre-determined NI margin, careful consideration should be 
given to its selection: this may encompass expert trialists actively interacting with 
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regulatory agencies. Likewise, the rationale for choosing this parameter needs to be 
clearly documented in the trial protocol and properly reported in the eventual 
publication. 
The choice of a relative or absolute margin remains a topic of debate: to date, no 
consensus has been reached amongst experts or agencies. Similar to too narrow a NI 
margin making a trial unfeasible, enforced use of relative scales for the NI margin may 
restrict some new technologies entering the market. Having said this, the data presented 
from the above stent trials should raise concern about the deliberate use of absolute 
margins and its consequences. Active research areas which repeatedly use non-
inferiority designs, such as coronary stents, require a better consensus regarding the 
consistent choice of non-inferiority margins. 
In contrast, non-inferiority trials evaluating drugs tend to use a relative rather than 
absolute risk when choosing a NI margin. A controversy over the potential risk of 
myocardial infarction in diabetic patients taking rosiglitazone (eventually not 
confirmed) lead to the FDA and EMA mandating cardiovascular safety outcomes for all 
diabetic medications. Following this mandate, in 2007, numerous non-inferiority trials 
have been carried out in this field. Of note these trials have a common approach (as 
recommended by FDA guidance) all using a relative risk of 1.3(11,15). 
Thankfully nowadays we observe relatively low primary event rates with most drug and 
device trials in cardiology. However, this provides a real challenge for non-inferiority 
trials. The anticipated event rate in a trial´s control arm should be sensible and justified, 
based on the most recent, contemporaneous and comparable patient cohort i.e. meta-
analysis, trial or registries. The trialists should explain their choice of event rate in the 
trial protocol.   
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Despite the best efforts of trialists, the event rate may be difficult to predict and is often 
lower than expected. To tackle this issue which occurs commonly in the field of 
coronary stents, expected event rates should perhaps be adjusted downwards in advance. 
Alternatively, to avoid problems of unexpected lower event rates occurring, one should 
use blinded interim results to gain insight as to whether the trial size should be increased 
or eligibility shifted to a higher risk population. Another possible solution is to 
recommend in advance an event-driven follow-up duration in order to achieve the 
desirable event rate with a fixed number of patients. 
The drawback of adopting relative NI margins and adjusting the trial´s design for 
eventual event rate decreases, is that the target trial size may not be attainable. When 
evaluating the viability of a NI trial, the investigator should reflect on the need for a NI 
design and what does the new treatment add to our knowledge and patient benefit. 
Several late generation stents developed over the past decade have for the most part 
been assessed in non-inferiority trials compared with Xience V. Despite the volume of 
trials and financial investment, we have not witnessed a substantial clinical 
improvement with these later generation stents. Nevertheless, successive subtle 
technological improvements in these devices have led to highly developed platforms, 
enhancing the feasibility of percutaneous coronary revascularization and providing 
treatment to a wider patient population.  
Moreover, as a scientific community we must reflect on our use (or abuse) of the NI 
design in the field of coronary stents. Although some consensus has been reached in this 
field (34), a consistent choice of NI margin should be considered to ensure preservation 
of the original benefit gained in the predecessor superiority trials. Furthermore, special 
caution is required when a new device or therapy is proposed as a novel concept based 
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upon a potential ancillary benefit (e.g. biorresorbable scaffolds). In these cases, the 
pivotal patient-oriented trials may prove inconclusive (or even controversial).  
 
CONCLUSIONS 
As the scientific community becomes more acquainted with cautiously interpreting 
results based on p values(35,36), readers should be aware that the conclusions of a non-
inferiority trial do not rely entirely on a test for non-inferiority or an upper confidence 
interval bound exceeding a limit. Careful interpretation of the absolute and relative 
magnitudes of difference between treatments, clinical relevance of events and 
supplementary benefits of the tested therapy should be taken into account to draw 
meaningful conclusions from each non-inferiority trial (Central illustration).  
Non-inferiority trials can be particularly sensitive to bias due to deficiencies in their 
design and execution. As discussed above it is important to ensure compliance with the 
correct methodology for their conduct. However, with regard to certain issues, absolute 
or relative NI margins, and NI magnitude selection, a clearer consensus would be 
beneficial.  
Overall, non-inferiority designs have an important role in cardiovascular therapeutics, 
and especially in evaluating new coronary stents. We hope our methodological 
perception illustrated by recent examples, are of value in enhancing the 
statistical/scientific quality of future non-inferiority trials. 
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FIGURE 1: Forest plot with differences and two-sided CI´s showing eight 
hypothetical outcomes from a non-inferiority trial. Thick dashed vertical line 
indicates zero difference, neutrality i.e. absolute difference equal to 0 or relative 
difference (RR, OR, HR) equal to 1. Short dashed vertical line indicates the established 
NI margin. 
 
FIGURE 2: Forest plot of CI´s for absolute differences and relative risks from 9 
stent trials. Inverted triangle represents the pre-specified absolute and relative NI 
margins. 
 
CENTRAL ILLUSTRATION. Challenges in the design and interpretation of non-
inferiority trials. 
 
